Kazia Therapeutics(KZIA)
Australia - SydneyBiotechnology
Focus: Kazia Therapeutics is a clinical-stage oncology biotech headquartered in Sydney, Australia, focused on brain cancer and CNS malignancies with a lead program (Paxalisib) in Phase 2 trials. The company is publicly traded (KZIA) and operates a lean, research-driven model targeting high-unmet-need indications.
Profile data last refreshed Yesterday · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Open Jobs
0
About Kazia Therapeutics
AI assessmentNot HiringNo open roles listed right now. Follow Kazia Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Early-stage
14 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
PHASE_1
Clinical Trials (1)
NCT00022295Phenoxodiol in Treating Patients With Refractory Solid Tumors
Phase 1Help build intelligence for Kazia Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.